Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker (BRKR) has announced a quarterly cash dividend payment of $0.05 per share on its common stock. The dividend will be distributed on December 16, 2024 to shareholders who are recorded as stockholders as of December 2, 2024. This decision was approved by the company's Board of Directors.
Bruker (BRKR) has announced its participation in three upcoming investor conferences. Executive Vice President & CFO Gerald Herman will represent the company at the Stifel 2024 Healthcare Conference in New York on November 18, the Wolfe Research 2024 Healthcare Conference in New York on November 19, and the Nasdaq 51st Investor Conference in London on December 10, 2024.
Live audiovisual webcasts will be available on Bruker's Investor Relations website, with replays accessible for 90 days after the events.
Bruker (NASDAQ: BRKR) has announced EpicIF, a breakthrough technology for their CellScape Spatial Proteomics platform. This enhancement expands compatible fluorophore conjugated antibodies by nearly 10-fold and increases throughput up to 2-fold while maintaining tissue integrity. The technology combines a proprietary reagent with visible light to erase fluorescence signals from almost any fluorophore.
Alongside EpicIF, Bruker is releasing new CellScape Navigator software with an improved user interface. Both upgrades will be available for existing CellScape instruments, offering enhanced flexibility in multiplexed immunofluorescence experiments and compatibility with additional fluorescent readouts like RNA-ISH.
Bruker (BRKR) reported Q3 2024 revenues of $864.4 million, up 16.4% year-over-year, with organic revenue growth of 3.1%. The company's GAAP diluted EPS was $0.27, while non-GAAP diluted EPS reached $0.60. Despite posting double-digit CER revenue growth, Bruker lowered its FY2024 guidance due to biopharma and China recovery delays. The updated guidance projects revenue between $3.34 to $3.37 billion, implying organic revenue growth of 3-4%, and non-GAAP EPS of $2.36-$2.41.
Bruker (Nasdaq: BRKR) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss results and business trends. Investors can access the webcast through the company's IR website and a slide presentation will be available. Pre-registration is available for expedited call access, and a replay will be accessible until December 5, 2024.
Bruker (Nasdaq: BRKR) announces significant advancements in 4D-Proteomics at the 23rd Human Proteome Organization World Congress. Key developments include:
1. Enhanced specificity and proteome coverage using diagonal-PASEF.
2. Achievement of a one-hundred dollar deep, high-accuracy plasma proteome analysis.
3. Introduction of high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2.
4. Increased peptide and protein identifications with ML-enhanced TIMSrescore.
5. Introduction of multiomics visualization and insights for proteomics and metabolomics.
These advancements enable robust, unbiased, and affordable proteomics with high-specificity protein identification and quantification, suitable for large-scale plasma proteomics studies.
Bruker (Nasdaq: BRKR) announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the '928 Patent') asserted by 10x Genomics against NanoString's CosMx® Spatial Molecular Imager (SMI) products in Europe. This ruling follows a similar decision by the German Federal Patent Court in May 2024, which declared the patent invalid in Germany. The UPC's decision extends the invalidation to France and The Netherlands.
The ruling is subject to appeal. Bruker awaits an additional hearing on a related patent (European Patent 4108782B1) and expects it to be declared invalid as well. The European Patent Office has issued a preliminary opinion considering this patent invalid, with a hearing scheduled for March 18, 2025.
Bruker (Nasdaq: BRKR) has announced the formation of a new division, Bruker Spatial Biology, offering comprehensive solutions for spatial biology research. This division brings together NanoString Technologies, Canopy Biosciences, and Bruker Spatial Genomics (formerly Acuity Spatial Genomics).
The new division will focus on advancing biomedical research with a suite of spatial biology instruments, assays, software, data analytics, and CRO services. Its portfolio includes NanoString's GeoMx®, CosMx™, and AtoMx™, Canopy Biosciences' CellScape™, and NanoString's nCounter® for gene expression analysis.
Bruker Spatial Biology aims to provide tailored solutions for customers' unique spatial research needs, offering choices across the spectrum from discovery to translational research. The division will showcase its technologies at the Society for Immunotherapy of Cancer (SITC) 2024 from November 8-10 in Houston, Texas.
Bruker (Nasdaq: BRKR) has unveiled the OptoVolt™ module at the Neuroscience 2024 conference, enhancing their Ultima multiphoton microscope platform for advanced neuroscience research. This innovative solution enables imaging speeds beyond 1000 frames per second, allowing researchers to capture millisecond dynamics of neural communication at single neuron resolution.
The OptoVolt module addresses challenges in voltage imaging with its ultrafast scanner technology and high signal-to-noise ratio. When combined with Bruker's NeuraLight 3D Ultra® spatial light modulator, it enables researchers to probe input-output relationships of neural ensembles at unprecedented temporal and spatial resolutions.
Professor Thomas Clandinin from Stanford University expressed excitement about the potential of voltage imaging in neural circuit investigation and systems neuroscience. Xiaomei Li, Ph.D., Vice President at Bruker, emphasized the company's commitment to addressing evolving research needs through customer collaboration.
Bruker (Nasdaq: BRKR) has acquired Dynamic Biosensors GmbH, a Munich-based pioneer in biosensor development. This acquisition enhances Bruker's biophysical portfolio for analyzing molecular interactions and kinetics in drug discovery and basic research. Dynamic Biosensors' innovative technologies include:
1. The heliXcyto instrument for single-cell Interaction Cytometry (scIC)
2. The heliX+ instrument using switchSENSE® technology with DNA nanolevers
These complement Bruker's Surface Plasmon Resonance (SPR) portfolio, including the new SPR #64 'Triceratops' and Sierra-Pro SPR systems. The combined Bruker Biosensors business now offers a comprehensive range of instruments, workflows, and consumables for studying inter-molecular and molecule-cell interactions in drug discovery. Financial details were not disclosed, but Bruker expects additional revenues greater than $5 million from the acquisition in FY2025, with no material EPS impact.
FAQ
What is the current stock price of Bruker Corporation (BRKR)?
What is the market cap of Bruker Corporation (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
